Antiviral drug discovery: preparing for the next pandemic

Catherine S Adamson; Kelly Chibale; Rebecca J M Goss; Marcel Jaspars; David J Newman; Rosemary A Dorrington

doi:10.1039/d0cs01118e

Antiviral drug discovery: preparing for the next pandemic

Catherine S Adamson, Kelly Chibale, Rebecca J M Goss, Marcel Jaspars, David J Newman, Rosemary A Dorrington^* (Corresponding Author)

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

121 Citations (Scopus)

15 Downloads (Pure)

Abstract

Clinically approved antiviral drugs are currently available for only 10 of the more than 220 viruses known to infect humans. The SARS-CoV-2 outbreak has exposed the critical need for compounds that can be rapidly mobilised for the treatment of re-emerging or emerging viral diseases, while vaccine development is underway. We review the current status of antiviral therapies focusing on RNA viruses, highlighting strategies for antiviral drug discovery and discuss the challenges, solutions and options to accelerate drug discovery efforts.

Original language	English
Pages (from-to)	3647-3655
Number of pages	9
Journal	Chemical Society Reviews
Volume	50
Issue number	6
Early online date	1 Feb 2021
DOIs	https://doi.org/10.1039/d0cs01118e https://doi.org/10.1039/d1cs90064a
Publication status	Published - 21 Mar 2021

Bibliographical note

Acknowledgements
The authors also gratefully acknowledge financial support from the South African Medical Research Council (MRC) with funds received from the South African National Department of Health and the UK Government's Newton Fund (R. A. D., RL. M. G., K. C.), the UK Engineering and Physical Sciences Research Council EQATA (R. J. M. G.), the UK Global Challenge Research Fund (R. J. M. G., R. A. D.), the University of Cape Town (K. C.) and the South African Research Chairs Initiative of the Department of Science and Innovation, administered through the South African National Research Foundation (NRF) to K. C. (UID: 64767) and R. A. D. (UID: 87583). C. S. A. acknowledges financial support for SARS-CoV-2/Covid-19 research from UKMRC (CVG-1725-2020) and UKRI-DHSC (MR/Vo28464/1). The authors acknowledge Bronwyn Tweedie of the Rhodes University Print Services Unit who provided the graphics for Fig. 1 and thank Gordon Cragg for his insightful comments and encouragement during the preparation of this manuscript.

Erratum: Antiviral drug discovery: Preparing for the next pandemic (Chem. Soc. Rev.( 2021) 50 (3647–3655) DOI: 10.1039/D0CS01118E)

Keywords

Antiviral Agents/chemistry
Biological Products/chemistry
COVID-19/drug therapy
Coronavirus Protease Inhibitors/chemistry
Drug Discovery/methods
Humans
Molecular Docking Simulation
Molecular Targeted Therapy/methods
Nucleic Acid Synthesis Inhibitors/chemistry
Pandemics/prevention & control
RNA, Viral/antagonists & inhibitors
SARS-CoV-2/chemistry
Small Molecule Libraries/chemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1039/d0cs01118eLicence: CC BY-NC
10.1039/d1cs90064a

Adamson_AntiviralDrugDiscovery_VOR
https://creativecommons.org/licenses/by-nc/4.0/
Final published version, 2.25 MBLicence: CC BY-NC

Cite this

@article{244416dfe24d468b85a5bd615ab84df9,

title = "Antiviral drug discovery: preparing for the next pandemic",

abstract = "Clinically approved antiviral drugs are currently available for only 10 of the more than 220 viruses known to infect humans. The SARS-CoV-2 outbreak has exposed the critical need for compounds that can be rapidly mobilised for the treatment of re-emerging or emerging viral diseases, while vaccine development is underway. We review the current status of antiviral therapies focusing on RNA viruses, highlighting strategies for antiviral drug discovery and discuss the challenges, solutions and options to accelerate drug discovery efforts.",

keywords = "Antiviral Agents/chemistry, Biological Products/chemistry, COVID-19/drug therapy, Coronavirus Protease Inhibitors/chemistry, Drug Discovery/methods, Humans, Molecular Docking Simulation, Molecular Targeted Therapy/methods, Nucleic Acid Synthesis Inhibitors/chemistry, Pandemics/prevention & control, RNA, Viral/antagonists & inhibitors, SARS-CoV-2/chemistry, Small Molecule Libraries/chemistry",

author = "Adamson, {Catherine S} and Kelly Chibale and Goss, {Rebecca J M} and Marcel Jaspars and Newman, {David J} and Dorrington, {Rosemary A}",

note = "Acknowledgements The authors also gratefully acknowledge financial support from the South African Medical Research Council (MRC) with funds received from the South African National Department of Health and the UK Government's Newton Fund (R. A. D., RL. M. G., K. C.), the UK Engineering and Physical Sciences Research Council EQATA (R. J. M. G.), the UK Global Challenge Research Fund (R. J. M. G., R. A. D.), the University of Cape Town (K. C.) and the South African Research Chairs Initiative of the Department of Science and Innovation, administered through the South African National Research Foundation (NRF) to K. C. (UID: 64767) and R. A. D. (UID: 87583). C. S. A. acknowledges financial support for SARS-CoV-2/Covid-19 research from UKMRC (CVG-1725-2020) and UKRI-DHSC (MR/Vo28464/1). The authors acknowledge Bronwyn Tweedie of the Rhodes University Print Services Unit who provided the graphics for Fig. 1 and thank Gordon Cragg for his insightful comments and encouragement during the preparation of this manuscript. Erratum: Antiviral drug discovery: Preparing for the next pandemic (Chem. Soc. Rev.( 2021) 50 (3647–3655) DOI: 10.1039/D0CS01118E)",

year = "2021",

month = mar,

day = "21",

doi = "10.1039/d0cs01118e",

language = "English",

volume = "50",

pages = "3647--3655",

journal = "Chemical Society Reviews",

issn = "0306-0012",

publisher = "Royal Society of Chemistry",

number = "6",

}

TY - JOUR

T1 - Antiviral drug discovery

T2 - preparing for the next pandemic

AU - Adamson, Catherine S

AU - Chibale, Kelly

AU - Goss, Rebecca J M

AU - Jaspars, Marcel

AU - Newman, David J

AU - Dorrington, Rosemary A

N1 - Acknowledgements The authors also gratefully acknowledge financial support from the South African Medical Research Council (MRC) with funds received from the South African National Department of Health and the UK Government's Newton Fund (R. A. D., RL. M. G., K. C.), the UK Engineering and Physical Sciences Research Council EQATA (R. J. M. G.), the UK Global Challenge Research Fund (R. J. M. G., R. A. D.), the University of Cape Town (K. C.) and the South African Research Chairs Initiative of the Department of Science and Innovation, administered through the South African National Research Foundation (NRF) to K. C. (UID: 64767) and R. A. D. (UID: 87583). C. S. A. acknowledges financial support for SARS-CoV-2/Covid-19 research from UKMRC (CVG-1725-2020) and UKRI-DHSC (MR/Vo28464/1). The authors acknowledge Bronwyn Tweedie of the Rhodes University Print Services Unit who provided the graphics for Fig. 1 and thank Gordon Cragg for his insightful comments and encouragement during the preparation of this manuscript. Erratum: Antiviral drug discovery: Preparing for the next pandemic (Chem. Soc. Rev.( 2021) 50 (3647–3655) DOI: 10.1039/D0CS01118E)

PY - 2021/3/21

Y1 - 2021/3/21

N2 - Clinically approved antiviral drugs are currently available for only 10 of the more than 220 viruses known to infect humans. The SARS-CoV-2 outbreak has exposed the critical need for compounds that can be rapidly mobilised for the treatment of re-emerging or emerging viral diseases, while vaccine development is underway. We review the current status of antiviral therapies focusing on RNA viruses, highlighting strategies for antiviral drug discovery and discuss the challenges, solutions and options to accelerate drug discovery efforts.

AB - Clinically approved antiviral drugs are currently available for only 10 of the more than 220 viruses known to infect humans. The SARS-CoV-2 outbreak has exposed the critical need for compounds that can be rapidly mobilised for the treatment of re-emerging or emerging viral diseases, while vaccine development is underway. We review the current status of antiviral therapies focusing on RNA viruses, highlighting strategies for antiviral drug discovery and discuss the challenges, solutions and options to accelerate drug discovery efforts.

KW - Antiviral Agents/chemistry

KW - Biological Products/chemistry

KW - COVID-19/drug therapy

KW - Coronavirus Protease Inhibitors/chemistry

KW - Drug Discovery/methods

KW - Humans

KW - Molecular Docking Simulation

KW - Molecular Targeted Therapy/methods

KW - Nucleic Acid Synthesis Inhibitors/chemistry

KW - Pandemics/prevention & control

KW - RNA, Viral/antagonists & inhibitors

KW - SARS-CoV-2/chemistry

KW - Small Molecule Libraries/chemistry

UR - http://www.scopus.com/inward/record.url?scp=85102078050&partnerID=8YFLogxK

U2 - 10.1039/d0cs01118e

DO - 10.1039/d0cs01118e

M3 - Article

C2 - 33524090

SN - 0306-0012

VL - 50

SP - 3647

EP - 3655

JO - Chemical Society Reviews

JF - Chemical Society Reviews

IS - 6

ER -

Antiviral drug discovery: preparing for the next pandemic

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this